Checkpoint Therapeutics
CKPT
CKPT was delisted on the 29th of May, 2025.
53 hedge funds and large institutions have $34.3M invested in Checkpoint Therapeutics in 2020 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 20 increasing their positions, 11 reducing their positions, and 3 closing their positions.
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
148% more capital invested
Capital invested by funds: $13.8M → $34.3M (+$20.5M)
82% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 11
18% more funds holding
Funds holding: 45 → 53 (+8)
6.7% more ownership
Funds ownership: 14.52% → 21.22% (+6.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$6.3M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.24M |
| 3 |
BlackRock
New York
|
+$1.77M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.74M |
| 5 |
FWM
Frontier Wealth Management
Kansas City,
Missouri
|
+$850K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$84.9K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$44K |
| 3 |
SG Americas Securities
New York
|
-$44K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$40.6K |
| 5 |
JP Morgan Chase
New York
|
-$26.3K |
CKPT Hedge Fund Activity: Q3 2020 in Review
53 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Checkpoint Therapeutics (CKPT) for Q3 2020, worth a combined $34.3M — up 148% from $13.8M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new CKPT positions and 3 closed out — a net gain of 8 holders — while 20 added to existing stakes and 11 trimmed.
The largest buyer was CVI Holdings, opening a new position worth an estimated $6.3M. The largest seller was Acadian Asset Management, cutting an estimated $84.9K.
- 53 institutional investors held Checkpoint Therapeutics (CKPT) as of Q3 2020, up from 45 in Q2 2020.
- Funds reported $34.3M of Checkpoint Therapeutics stock for Q3 2020, up 148% quarter-over-quarter.
- 11 funds opened new Checkpoint Therapeutics positions in Q3 2020 and 3 closed out, a net change of +8 holders.
- The largest Checkpoint Therapeutics buyer in Q3 2020 was CVI Holdings, an estimated $6.3M added.
- The largest Checkpoint Therapeutics seller in Q3 2020 was Acadian Asset Management, an estimated $84.9K sold.
Based on aggregated 13F filings for Q3 2020.